Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.
Feuerstein graduated from Emory University with a bachelor's degree in political science.
Recent Articles By The Author
Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects
'We're seeing impressive, early responses with BB2121 without the toxicity,' says Bluebird CEO Nick Leschly.
Biotech Stock Mailbag: Looking for an Investable Idea in Alzheimer's Minefield
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
CytRx CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA
CytRx announced a plan Tuesday to seek U.S. marketing approval of aldoxorubicin based more on hocus-pocus than credible study results.
Amicus Tumbles on Lengthy Delay to U.S. Fabry Drug FDA Filing Plan
The U.S. Food and Drug Administration turned down Amicus' request to seek accelerated approval for Galafold based on an existing kidney biomarker data.
Biotech School: How to Use Kaplan-Meier Survival Curves to Become a Smarter Investor
Interpreting 'K-M curves' correctly is an important tool for biotech investors.